Short-interval Mammography Research Articles

Mammographic Surveillance in Older Women With Breast Cancer in Canada and the United States: Are We Choosing Wisely?

PurposeGuidelines on mammographic surveillance after breast cancer treatment have been disseminated internationally and incorporated into Choosing Wisely recommendations to reduce low-value care. However, adherence within different countries before their publication is unknown. Methods and MaterialsLow-value mammography, defined as “short-interval” (within 6 months of radiation) or “high-frequency” (>1 within 12 months of radiation), was compared in Medicare fee-for-service in the United States and Ontario, Canada. Women ≥65 years diagnosed with breast cancer who underwent breast-conserving therapy with a minimum of 24 months of follow-up were included (n = 19,715 United States; 6479 Ontario). Secondary outcomes were patient and physician characteristics associated with discordance. ResultsShort-interval mammography was higher in the United States than in Ontario (55.9% vs 38.0%, P < .001), as was high-frequency (39.6% vs 7.9%, P < .001). In Ontario, younger age (42% ≥85 vs 58% <74 years, P < .001) and chemotherapy (69% vs 51%, P < .001) were associated with short-interval mammography; in the United States, age, earlier diagnosis year, stage, chemotherapy, rurality, and academic center treatment were associated with greater use. Chemotherapy was associated with high-frequency mammography in both countries (13% vs 7% in Ontario, P < .001; 69% vs 51% in United States, P = .02); younger age, earlier diagnosis year, stage, and nonacademic center treatment were associated in the United States. In both countries, radiation oncologists had the highest proportion of providers ordering low-value mammograms. ConclusionsDespite significant evidence guiding surveillance mammography recommendations, there are high rates of short-interval mammography in both the United States and Ontario, and high rates of high-frequency mammography in the United States. Further international efforts, such as Choosing Wisely, are needed to reduce low-value mammography.

Is Short-Interval Mammography Necessary After Breast Conservation Surgery and Radiation Treatment in Breast Cancer Patients?

The optimum timing and frequency of mammography in breast cancer patients after breast-conserving therapy (BCT) are controversial. The American Society of Clinical Oncology recommends the first posttreatment mammogram 1 year after diagnosis but no earlier than 6 months after completion of radiotherapy. The National Comprehensive Cancer Network recommends annual mammography. Intermountain Healthcare currently follows a more frequent mammography schedule during the first 2 years in BCT patients. This retrospective study was undertaken to determine the cancer yield mammography during the first 2 years after BCT. 1,435 patients received BCT at Intermountain Healthcare between 2003 and 2007, inclusive. Twenty-three patients had bilateral breast cancer (1,458 total breasts). Patients were followed up for 24 months after diagnosis. The 1- and 2-year mammography yields were determined and compared with those of the general screening population. 1,079 breasts had mammography at less than 1 year, and two ipsilateral recurrences (both noninvasive) were identified; 1,219 breasts had mammography during the second year, and nine recurrences (three invasive, six noninvasive) were identified. Of the 11 ipsilateral recurrences during the study, three presented with symptoms and eight were identified by mammography alone. The mammography yield was 1.9 cancers per 1,000 breasts the first year and 4.9 per 1,000 the second year. These data demonstrate that the mammography yield during the first 2 years after BCT is not greater than that in the general population, and they support the policy for initiating followup mammography at 1 year after BCT.

Benefits of Short-Interval Mammography Questioned

Benefits of Short-Interval Mammography Questioned

Value of Short Interval Mammography following Breast Conservation

The optimum timing and frequency of mammograms in breast cancer patients following breast-conserving therapy (BCT) are controversial. The National Comprehensive Cancer Network (NCCN) guidelines currently recommend a mammogram 6-12 months following radiation. The American Society of Clinical Oncology (ASCO) recommends the first post-treatment mammogram 1 year after diagnosis, but no earlier than 6 months after completion of radiotherapy. The Intermountain Healthcare policy is for patients to undergo mammography every six months for two years following BCT before they return to annual screening.

Moving Mammogram-Reluctant Women to Screening: A Pilot Study

Effective interventions are needed for women long overdue for screening mammography. The purpose of this study is to pilot test an intervention for motivating overdue women to receive a mammogram. Subjects aged 45-79 without a mammogram in > or =27 months and enrolled in study practices were identified from claims data. The intervention included a mailed, educational booklet, computer-assisted barrier-specific tailored counseling and motivational interviewing, and facilitated, short-interval mammography scheduling. Of 127 eligible women, 45 (35.4%) agreed to counseling and data collection. Most were > or =3 years overdue. Twenty-six (57.8%) of the counseled women got a mammogram within 12 months. Thirty-one (72.1%) of 43 counseled women moved > or =1 stage closer to screening, based on a modified Precaution Adoption Process Model. It is feasible to reach and counsel women who are long overdue for a mammogram and to advance their stage of adoption. The intervention should be formally evaluated in a prospective trial comparing it to control or to proven interventions.

MR imaging in probably benign lesions (BI-RADS category 3) of the breast

Purpose To investigate the role of dynamic magnetic resonance (MR) imaging in the evaluation of probably benign lesions (BI-RADS category 3) and its contribution to patient management. Materials and methods Dynamic breast MR imaging was performed in 56 lesions assessed as probably benign in mammography of 43 patients. In MR imaging, T2-weighted turbo spin echo (TSE) with fat suppression sequence followed by pre- and post-contrast T1-weighted 3D-FLASH sequences were used. MR imaging findings were scored using 0–2 point criterion scale. The lesions were divided into five groups according to their total score (0 point: group 1, negative; 1–2 points: group 2, benign; 3 points: group 3, probably benign; 4–5 points: group 4, suspicious for malignancy; 6–8 points: group 5, highly suggestive of malignancy). Histopathologic verification of lesions in group 4 and above was obtained. Lesions in group 3 were either biopsied or followed up by mammography or MR imaging. Lesions in group 1–2 were followed by mammography of 6-month intervals for 2 years. The sensitivity, specificity, accuracy, and positive and negative predictive values of MR imaging in the determination of malignancy in BI-RADS category 3 lesions were calculated. Results Fifty-six findings (45 mass, 9 breast tissue, 2 focal enhancement) in 43 patients were detected in MR imaging. According to their total score, 41 lesions (73.2%) and breast tissue had 0 point (group 1); 10 lesions (17.8%) had 1–2 points (group 2); 2 lesions (3.6%) had 3 points (group 3); 2 lesions (3.6%) had 4 and 5 points (group 4); and 1 lesion (1.8%) had 6 points (group 5). Ten lesions (of six in groups 1 and 2, one in group 3, three in groups 4 and 5) were histopathologically confirmed. Out of 10 lesions, only 1 (1.8%) with 4 points in group 4 was diagnosed as invasive ductal carcinoma. Other lesions followed with mammography or MR imaging did not change. The sensitivity, specificity, accuracy, positive and negative predictive values of MR imaging in the determination of malignancy in BI-RADS category 3 lesions were calculated as 100, 96.4, 96.4, 33.3, and 100%, respectively. Conclusion In the evaluation of BI-RADS category 3 lesions, dynamic MR imaging does not provide additional information with low positive predictive value similar to that of short interval mammography follow-up.